Drugs / trifluridine/tipiracil
trifluridine/tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02848443 | May 2016 → Aug 2019 | colorectal cancer | Servier | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02848443 ↗ |
| Known as | S 95005 | “Trifluridine/tipiracil hydrochloride (S 95005)” NCT02848443 ↗ |
| Known as | Trifluridine/tipiracil hydrochloride | “Trifluridine/tipiracil hydrochloride (S 95005)” NCT02848443 ↗ |
| Route | Oral | “given orally at the dose of 25 or 30 or 35 mg/m2/dose” NCT02848443 ↗ |